Leveraging patient-centered strategies and data analytics, our capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, a novel approach to site and patient access, and comprehensive lab services via PPD® Laboratories. We serve pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships, functional service partnerships and PPD® Biotech, for biotech and small to midsize pharma companies.
In an increasingly complex research landscape, biopharmaceutical leaders can depend on PPD for quality performance, continual innovation and trusted partnership.
PPD: Dedicated to helping deliver life-changing therapies
Apr 02, 2020
PPD, Inc. (Nasdaq:PPD) has been named by IDG’s CIO as a 2020 CIO 100 Awards honoree for deploying a data-visualization platform enabling PPD to more quickly visualize targeted patient populations and investigator sites conducting clinical trials for pharmaceutical and biotech customers, helping speed the development of life-changing medicines.
Mar 10, 2020
PPD, Inc. (Nasdaq:PPD) today announced the cancellation of its fireside chat and related webcast at the Barclays Global Healthcare Conference, previously scheduled for Wednesday, March 11, at 11:45 a.m. (U.S. Eastern Time), as a result of the conference switching to a virtual format.
PPD Common Stock
Copyright West LLC. Minimum 15 minutes delayed.